Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Operating Leases (2022 - 2026)

Compass Therapeutics' Operating Leases history spans 5 years, with the latest figure at $9.8 million for Q1 2026.

  • On a quarterly basis, Operating Leases rose 53.44% to $9.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $9.8 million, a 53.44% increase, with the full-year FY2025 number at $8.8 million, up 40.23% from a year prior.
  • Operating Leases hit $9.8 million in Q1 2026 for Compass Therapeutics, up from $8.8 million in the prior quarter.
  • Over the last five years, Operating Leases for CMPX hit a ceiling of $9.8 million in Q3 2025 and a floor of $189000.0 in Q1 2024.
  • Historically, Operating Leases has averaged $4.7 million across 5 years, with a median of $4.5 million in 2023.
  • Biggest five-year swings in Operating Leases: tumbled 92.85% in 2024 and later surged 3276.19% in 2025.
  • Tracing CMPX's Operating Leases over 5 years: stood at $1.8 million in 2022, then tumbled by 70.84% to $536000.0 in 2023, then surged by 1074.63% to $6.3 million in 2024, then soared by 40.23% to $8.8 million in 2025, then increased by 10.9% to $9.8 million in 2026.
  • Business Quant data shows Operating Leases for CMPX at $9.8 million in Q1 2026, $8.8 million in Q4 2025, and $9.8 million in Q3 2025.